THE FSA SAFETY ASSESSMENT OF RP 427
IF YOU ARE A BRAND WHO FUNDED APPLICATION RP 427, THEN DEPENDING UPON YOUR PRODUCT TYPES AND THEIR STRENGTHS, THE OUTCOMES OF THE SAFETY ASSESSMENT MIGHT BE “SWEET”, “BITTERSWEET” OR JUST DOWNRIGHT “BITTER”
A (very) qualified congratulations is in order to those who run EIHA, their application RP427 is to be recommended for Authorisation in due course and they will no doubt give themselves a congratulatory pat on the back for what they have achieved. Whether the Brands that paid for the application would contribute to the patting or would prefer their hands to be swapped for knives is up to them.
Why do we suggest that any congratulations are qualified? An analysis of the assessment distills the following:
(a) EIHA supplied toxicology data which asserted that CBD could only be demonstrated as being safe at doses of up to 10mg per day* (see later note);
(b) EIHA charged all members of the consortium a fee, but only applied for Authorisation as a Novel Food for a very small, binary section of them; and,
(c) EIHA furthermore excluded most of those who fell within the already very selected application type to a single product.
Thus, despite the hundreds and hundreds of thousands of pounds which has been extracted from the members of the consortium, EIHA have succeed in securing a recommendation for CBD tinctures and liquid capsules made solely with Hempseed Oil (i.e. no other oil and no other product format) and only to a maximum daily intake of 10mg.
One comment
Pingback: Cannabis regulatory and business news for August 2024
Comments are closed.